Journal
CANCER PREVENTION RESEARCH
Volume 5, Issue 1, Pages 51-60Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1940-6207.CAPR-11-0256
Keywords
-
Categories
Funding
- NIH [1NO1 CN43302-WA19, 1G20RR025828-01]
- National Cancer Institute, NIH [P30CA051008]
- NATIONAL CANCER INSTITUTE [P30CA051008] Funding Source: NIH RePORTER
- NATIONAL CENTER FOR RESEARCH RESOURCES [G20RR025828] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Stem cell antigen-1 (Sca-1, Ly6A) is a glycerophosphatidylinositol (GPI)-anchored protein that was identified as a murine marker of bone marrow stem cells. Although Sca-1 is widely used to enrich for stem and progenitor cells in various tissues, little is known about its function and associated signaling pathways in normal and malignant cells. Here, we report that the absence of Sca-1 in the mammary gland resulted in higher levels of PPAR gamma and PTEN, and a reduction of pSer84PPAR gamma, pERK1/2, and PPAR delta. This phenotype correlated with markedly increased sensitivity of Sca-1 null mice to PPAR gamma agonist GW7845 and insensitivity to PPAR delta agonist GW501516. Reduction of Sca-1 expression in mammary tumor cells by RNA interference resulted in a phenotype similar to the Sca-1 deficient mammary gland, as evidenced by increased PPAR gamma expression and transcriptional activity, resulting in part from a lesser susceptibility to proteasomal degradation. These data implicate Sca-1 as a negative regulator of the tumor suppressor effects of PPAR gamma. Cancer Prev Res; 5(1); 51-60. (C)2011 AACR.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available